Arrakis CEO Discusses Challenges in Developing RNA-Targeting Cancer Drugs

Arrakis, a biotech startup led by Michael Gilman, is tackling the challenge of targeting the Myc oncogene, which is implicated in 70% of cancers and is difficult to target due to its "intrinsically disordered" protein structure. Instead of targeting the protein directly, Arrakis aims to intercept the mRNA responsible for its production, a novel approach in drug development.